Galena Biopharma Inc (GALE): Today's Featured Health Care Laggard

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Galena Biopharma ( GALE) pushed the Health Care sector lower today making it today's featured Health Care laggard. The sector as a whole closed the day up 0.9%. By the end of trading, Galena Biopharma fell $0.20 (-3.7%) to $5.19 on light volume. Throughout the day, 5,280,548 shares of Galena Biopharma exchanged hands as compared to its average daily volume of 8,278,100 shares. The stock ranged in price between $5.12-$5.46 after having opened the day at $5.41 as compared to the previous trading day's close of $5.39. Other companies within the Health Care sector that declined today were: Nanoviricides ( NNVC), down 24.0%, Alphatec Holdings ( ATEC), down 18.3%, Compugen ( CGEN), down 14.5% and Cambrex Corporation ( CBM), down 14.2%.

Galena Biopharma, Inc., a biopharmaceutical company, focuses on developing oncology treatments to address major unmet medical needs to advance cancer care. It is developing a pipeline of immunotherapy product candidates for the treatment of various cancers based on the E75 peptide. Galena Biopharma has a market cap of $518.8 million and is part of the drugs industry. Shares are down 0.6% year to date as of the close of trading on Monday. Currently there are 9 analysts that rate Galena Biopharma a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Galena Biopharma as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, weak operating cash flow and feeble growth in its earnings per share.

On the positive front, Dehaier Medical Systems ( DHRM), up 30.3%, Cadence Pharmaceuticals ( CADX), up 26.5%, Relypsa ( RLYP), up 18.9% and Stemline Therapeutics ( STML), up 17.5% , were all gainers within the health care sector with Merck ( MRK) being today's featured health care sector leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

For These Small-Cap Biotech CEOs, Stock Promotion, Not Drug Development, Was Priority No. 1

How to Dig Deep for Value in These Exuberant Markets

Value Investors Have to Go Deeper

Gilead Sciences Leads Biotech Movers -- Plus Jim Cramer's Comments